• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Antiangiogenic therapy for ovarian cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Rosa, Daniela D
    Clamp, Andrew R
    Collinson, Fiona J
    Jayson, Gordon C
    Affiliation
    Cancer Research UK and University of Manchester, Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.
    Issue Date
    2007-09
    
    Metadata
    Show full item record
    Abstract
    PURPOSE OF REVIEW: To highlight the current antiangiogenic compounds being evaluated as single agents or in association with chemotherapy in the treatment of ovarian cancer, as well as the rationale for their development. RECENT FINDINGS: Several proangiogenic factors may be potential targets for antiangiogenic therapy in ovarian cancer. Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been evaluated as a single agent in two phase II clinical trials and in combination with chemotherapy in three phase II studies, with promising results. This agent is also being evaluated in association with chemotherapy in two phase III clinical trials, both in the treatment and in the maintenance settings. Heparanase inhibitors and inhibitors of platelet-derived growth factor signalling remain as potential agents to be investigated in phase II trials. The development of biomarkers to define appropriate dosing regimens and predict which patients may benefit from antiangiogenic therapies is of great importance. SUMMARY: Data from preclinical and clinical studies reported in the last 2 years demonstrate the importance of several proangiogenic factors in the prognosis of ovarian cancer, suggesting possible new targets for antiangiogenic therapy. The agents that are currently being investigated in phase II and III clinical trials include bevacizumab, erlotinib, sunitinib, sorafenib and vascular endothelial growth factor Trap, and the results of these trials will have significant implications in the future management of ovarian cancer.
    Citation
    Antiangiogenic therapy for ovarian cancer. 2007, 19 (5):497-505 Curr Opin Oncol
    Journal
    Current Opinion In Oncology
    URI
    http://hdl.handle.net/10541/70331
    DOI
    10.1097/CCO.0b013e32827035f0
    PubMed ID
    17762578
    Type
    Article
    Language
    en
    ISSN
    1040-8746
    ae974a485f413a2113503eed53cd6c53
    10.1097/CCO.0b013e32827035f0
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
    • Authors: Teoh D, Secord AA
    • Issue date: 2012 Mar
    • Antiangiogenic therapies in epithelial ovarian cancer.
    • Authors: Teoh DG, Secord AA
    • Issue date: 2011 Jan
    • Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
    • Authors: Aravantinos G, Pectasides D
    • Issue date: 2014
    • Where do antiangiogenic agents belong in the treatment algorithm for ovarian cancer?
    • Authors: Dizon DS
    • Issue date: 2013 Oct
    • Current status of anti-angiogenic agents in the treatment of ovarian carcinoma.
    • Authors: Sánchez-Muñoz A, Pérez-Ruiz E, Mendiola Fernández C, Alba Conejo E, González-Martín A
    • Issue date: 2009 Sep
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.